Myo-Inositol for PCOS: What 15 Years of Research Actually Shows (And the Dosing Mistake Most Women Make)

The Short Answer: What Myo-Inositol Does for PCOS

The three-sentence version

Myo-inositol improves how your cells respond to insulin, and because insulin resistance sits underneath so much of PCOS, that single change ripples outward into ovulation, androgens, and cycle regularity. Randomised trials have shown restored ovulation in roughly two thirds of women who weren’t ovulating, modest drops in free testosterone, improved HOMA-IR, and shorter, more predictable cycles. It’s cheap, it’s well tolerated, and the side effect profile is genuinely boring compared with metformin.

Who it tends to help most

Women with insulin-resistant PCOS phenotypes. If your fasting insulin is elevated, if you’ve got skin tags or darkened patches at the neck or armpits, if you crash hard ninety minutes after a bagel, if you’ve been told you’re “pre-diabetic” or borderline, you’re the population these trials recruited. Anovulatory women trying to conceive are the other clear win, which is where the strongest fertility data sits.

Who probably won’t notice much

Lean PCOS with normal insulin markers and a primarily adrenal androgen picture. Women whose main complaint is hirsutism and who expect it to resolve in six weeks. And anyone who takes 500mg a day because that’s what the bottle said.

Which brings me to the thing that bothers me most about how this supplement is sold.

The trial dose is 4,000mg daily. Four grams. The majority of positive studies used exactly that, split into two 2g doses. Walk into any pharmacy and you’ll find products delivering 500mg or 1,000mg per serving, and women dutifully take one, landing at a quarter of the dose that produced the results they read about. Then they conclude it doesn’t work.

Second mistake: quitting too early. Trials measured primary outcomes at 12 to 24 weeks. Ovulation restoration clustered around weeks 8 through 12. If you judge this at three weeks, you’ve learned nothing.

And then there’s the 40:1 question, the myo-to-D-chiro-inositol ratio that every product label shouts about and almost nobody explains. I’ll get to why that number exists, and why some high-D-chiro formulas may actively work against you.

What Myo-Inositol Actually Is (And Why Your Body Already Makes It)

Inositol isn’t a vitamin (despite being called B8)

You’ll see myo-inositol marketed as “vitamin B8.” It isn’t a vitamin. A vitamin is something your body can’t make and must obtain from food. Your body makes inositol from glucose, continuously, via a two-step enzymatic conversion. The B8 label is a historical leftover from the 1940s that stuck around because it sounds official on a label.

Chemically, it’s a cyclitol: a six-carbon sugar alcohol with a ring structure and six hydroxyl groups. Rearrange where those hydroxyls point and you get different stereoisomers.

The nine stereoisomers and the two that matter

There are nine. Myo-inositol is by far the most abundant in human tissue, making up over 90% of the body’s inositol pool. D-chiro-inositol (DCI) is the second one you need to know. Scyllo, muco, neo and the rest are mostly biochemical trivia for our purposes.

Your body produces DCI from myo-inositol using an enzyme called epimerase, and here’s the detail that matters for PCOS: that enzyme is insulin-dependent. Insulin drives the conversion. Hold onto that.

Where it shows up in food

Real amounts, because vague “found in fruits and vegetables” claims annoy me:

• Cantaloupe: among the densest sources, roughly 350mg per 100g in some analyses
• Citrus fruits: oranges and grapefruit run in the 100 to 200mg per 100g range (grapefruit juice is notably high)
• Beans and legumes: navy beans, lima beans, chickpeas, generally 100 to 300mg per 100g
• Buckwheat, bran and whole grains: high on paper, poor in practice
• Nuts and seeds: almonds, walnuts, decent contributors

That grain caveat is worth understanding. In cereals and brans, most inositol is locked up as phytic acid (phytate), a storage form with six phosphate groups attached. Humans produce very little phytase, so a lot of that inositol passes straight through you. The number on the food composition table is not the number your bloodstream sees.

Typical dietary intake lands somewhere between 225mg and 1,500mg per day depending on how much fruit and legume you eat. Which sounds like a lot until you compare it to the trial dose.

Your kidneys make about 4 grams a day

Endogenous synthesis runs around 4g daily, and the kidneys do most of the heavy lifting. So when you take 4,000mg of supplemental myo-inositol, you’re roughly doubling what your body produces on its own. That’s a meaningful pharmacological nudge, not a token.

One more concept before mechanism. In plasma, the myo-to-DCI ratio sits around 40:1. But in ovarian follicular fluid, healthy ratios run far higher, closer to 100:1. The follicle wants a lot of myo-inositol and very little DCI.

Think of myo-inositol as raw lumber and DCI as finished furniture. You need both. But PCOS appears to break the sawmill in a tissue-specific way, and the ovary ends up short on lumber.

How Myo-Inositol Works in PCOS: The Mechanism, Explained Without the Jargon

Second messengers and the insulin signal

When insulin docks onto its receptor on a cell surface, the receptor doesn’t personally go turn on glucose transport. It fires off intracellular messengers. Two of those messengers are inositol phosphoglycans (IPGs), and they’re built from, you guessed it, inositol.

The division of labour looks like this:

• Myo-inositol-IPG mediates glucose uptake, pushing GLUT4 transporters to the cell membrane so sugar can get in
• DCI-IPG mediates glycogen synthesis, the storage side of the equation

Run low on either messenger and the insulin receptor can be perfectly functional while the signal fizzles downstream. That’s post-receptor insulin resistance, and it’s a big part of the PCOS metabolic picture. Supplying the raw material restores signalling capacity.

The epimerase defect theory

Here’s where it gets interesting, and where the PCOS story diverges from generic insulin resistance.

Carlomagno, Unfer and colleagues proposed what’s become the dominant explanation: tissue-specific epimerase dysregulation. In muscle and fat tissue of women with PCOS, epimerase activity appears reduced, so there’s not enough DCI-IPG for glycogen storage. But in the ovary, chronic hyperinsulinaemia appears to drive epimerase into overdrive, over-converting myo-inositol into DCI and depleting the myo pool the follicle desperately needs.

Same enzyme. Opposite problems in different tissues. It’s a weirdly elegant hypothesis.

The follicular fluid data supports it. Work from Unfer’s group and separately from Heimark and colleagues (2014) examined inositol ratios directly in follicular fluid aspirated during egg retrieval. Healthy ovaries showed myo:DCI ratios near 100:1. PCOS samples came back dramatically altered, with some reported as low as 0.2:1. That’s not a rounding error. That’s a follicle swimming in the wrong isomer.

FSH signalling in the ovary

Myo-inositol isn’t just an insulin accessory in the ovary. Granulosa cells need it for FSH-mediated signal transduction and for aromatase expression (aromatase being the enzyme that converts androgens into oestrogen). A myo-inositol-depleted follicle responds poorly to FSH even when circulating FSH looks fine on your lab printout.

That’s the explanation I find most useful for a frustrating clinical pattern: women whose bloodwork looks “not that bad” but whose oocyte quality is poor and whose follicles stall out at 8 or 10mm.

Why this hits androgens too

Hyperinsulinaemia raises free testosterone through two separate doors.

Door one: insulin acts directly on ovarian theca cells, amplifying LH-driven androgen production. More insulin, more androgen output.

Door two: insulin suppresses hepatic production of sex hormone binding globulin (SHBG), the protein that mops up circulating testosterone and keeps it inactive. Less SHBG means a larger free, biologically active fraction even if total testosterone barely moves.

Improve insulin signalling and you nudge both doors shut. That’s why free testosterone tends to drop more than total testosterone in these trials, and why SHBG is a lab marker I’d actually track.

Several trials also report reduced LH and a normalised LH:FSH ratio, which fits the same story: less insulin-driven pituitary and ovarian overstimulation.

The AMH connection nobody talks about

A fair number of women arrive at myo-inositol because an AMH result terrified them. Values of 50, 70, 90 pmol/L on a PCOS panel look alarming if you’ve been taught AMH equals “ovarian reserve.”

In PCOS, high AMH largely reflects a crowded cohort of small antral follicles, each secreting AMH, rather than exceptional fertility. Multiple inositol trials have documented AMH reductions over three to six months. That isn’t your reserve dropping. It’s the follicle population normalising and the arrested small follicles either progressing or clearing. I think that effect is underappreciated, partly because AMH gets explained so badly in clinic.

Now, the honest caveat: the epimerase hypothesis is a hypothesis. Strongly supported, mechanistically coherent, consistent with the follicular fluid findings, and not settled science. Anyone presenting it as established fact is overselling.

The Evidence for Myo-Inositol for PCOS: Trial by Trial, With the Numbers

Ovulation and menstrual regularity

The foundational work came out of Italy in the mid-to-late 2000s. Gerli and colleagues ran randomised, double-blind, placebo-controlled trials (published in 2003 and again in 2007 in European Review for Medical and Pharmacological Sciences) looking at ovulatory function and metabolic markers. The headline figure that gets quoted everywhere: ovulation restored in roughly 70% of treated women versus around 20% on placebo. The 2007 trial used 4g myo-inositol plus 400mcg folic acid over 14 weeks and also documented increased HDL, reduced leptin, and improved insulin sensitivity.

Papaleo et al. (2007), in Gynecological Endocrinology, gave 4g myo-inositol plus folic acid to oligo-amenorrhoeic women with PCOS. Spontaneous ovulation returned in 72% of participants, and 40% achieved pregnancy within the follow-up window. Small study. Striking numbers.

Insulin resistance, HOMA-IR and glucose

This is the most consistent finding across the literature. Fasting insulin down, HOMA-IR down, improved glucose disposal on OGTT and on clamp-type measures in the better-designed studies. Effect sizes vary, but direction almost never does. If I had to bet on one outcome reproducing in a new trial tomorrow, it’d be this one.

Testosterone, SHBG and hirsutism

Costantino’s 2009 double-blind, placebo-controlled trial deserves more attention than it gets. Over 12 to 16 weeks with 4g daily, the treated group showed significant reductions in free testosterone, improved insulin sensitivity, increased HDL, falling triglycerides, and roughly an 11% reduction in diastolic blood pressure. That blood pressure finding surprised me, and it’s rarely mentioned in consumer coverage.

Hirsutism outcomes are softer. Modified Ferriman-Gallwey scores improve in some trials, barely budge in others, and the follow-up periods are usually too short for hair growth cycles to show their hand. I’d call hirsutism a possible slow benefit, not a selling point.

Fertility, IVF outcomes and oocyte quality

The assisted reproduction data is, to me, the most practically useful.

Papaleo’s 2009 IVF work found that myo-inositol pretreatment reduced the total gonadotropin dose required for stimulation and shortened stimulation duration, while improving oocyte quality. Ciotta and colleagues (2011) reported fewer immature oocytes and better embryo quality. Multiple ICSI trials echo the pattern: fewer degenerated oocytes, higher proportion of mature metaphase II eggs, better grade embryos.

Less gonadotropin for an equal or better egg yield is a real clinical outcome. It’s cheaper and it lowers hyperstimulation risk.

Head-to-head versus metformin

Raffone et al. (2010), in the Journal of Ovarian Research, compared 4g myo-inositol plus folic acid against metformin 1,500mg daily in 120 anovulatory women with PCOS. Ovulation rates came in at 65% for myo-inositol versus 50% for metformin. Pregnancy rates favoured inositol too (around 30% versus 18%).

But here’s what I’d emphasise over the efficacy numbers: tolerability. Metformin’s gastrointestinal side effects cause real-world dropout. Nausea, diarrhoea, metallic taste. Myo-inositol at 4g produces mild loose stool in some people and not much else. A drug you can actually keep taking beats a marginally stronger drug you abandon in week three.

That said, metformin has decades of long-term safety and outcome data behind it. Inositol doesn’t. If you have frank type 2 diabetes, metformin isn’t optional and inositol isn’t a substitute.

Weight, lipids and blood pressure

I’m going to be blunt. Don’t buy myo-inositol as a weight loss supplement. BMI effects across the literature are small and inconsistent, and where weight loss appears it’s usually modest and confounded by concurrent diet advice. Lipid improvements (HDL up, triglycerides down) show up more reliably, and the diastolic blood pressure signal appears in a handful of trials.

Mood, anxiety and the depression signal

Inositol has a separate psychiatric literature at much higher doses (12 to 18g daily for depression, panic disorder and OCD, from 1990s trials). Interesting, but that’s a different dose and a different question. Within PCOS trials, mood and quality-of-life improvements do appear, though they’re secondary outcomes and plausibly downstream of fewer blood sugar swings and returning cycles. I’d call any mood benefit at 4g a minor bonus rather than a reason to start.

The Cochrane review and what it actually concluded

The 2018 Cochrane review (Showell and colleagues) on inositol for subfertile women with PCOS is where enthusiasm meets a cold shower. Verdict: possible improvement in clinical pregnancy rate, but the evidence was graded low certainty. No clear effect on live birth. No clear effect on miscarriage.

Now, “low certainty” is a technical statement about trial quality, not a verdict that something doesn’t work. It means the included studies were small, variably designed, and not powered for live birth. The honest reading is “promising, inadequately tested,” not “debunked.”

Unfer’s group published a systematic review pooling multiple RCTs on hormonal and metabolic endpoints that came out considerably more favourable, and there’s extension data into metabolic syndrome and even postmenopausal women with a PCOS history showing metabolic benefit.

The methodological problems competitors skip

If you only read the glowing summaries, you’d miss this. So:

• Small samples. Many trials enrolled under 100 women. Several under 50.
• Geographic concentration. A striking proportion of this literature comes from a handful of Italian research groups. Independent replication elsewhere is thinner than you’d want.
• Industry involvement. Inositol supplement manufacturers have funded or been affiliated with a meaningful share of the research.
• Short durations. Twelve to twenty-four weeks is standard. Almost nothing runs for years.
• Diagnostic inconsistency. Rotterdam, NIH, AES criteria used variably, so “PCOS” isn’t the same population across trials.
• Live birth is the outcome that matters for fertility patients, and it’s the one least well studied.

Trial	Year	n	Dose	Duration	Primary outcome	Result
Gerli et al.	2007	92	4g MI + folic acid	14 wks	Ovulatory function	Ovulation frequency up; HDL up; leptin down
Papaleo et al.	2007	25	4g MI + folic acid	6 mo	Ovulation	72% ovulated; 40% pregnant
Costantino et al.	2009	42	4g MI + folic acid	12-16 wks	Metabolic/hormonal	Free T down; insulin sensitivity up; diastolic BP down ~11%
Papaleo et al. (IVF)	2009	60	4g MI + folic acid	Pre-cycle	Stimulation outcomes	Lower gonadotropin dose; better oocyte quality
Raffone et al.	2010	120	4g MI vs metformin 1.5g	6 mo	Ovulation/pregnancy	65% vs 50% ovulation; better tolerability
Nordio & Proietti	2012	50	MI alone vs 40:1 MI:DCI	3 mo	Metabolic/hormonal	40:1 combination outperformed MI alone
Cochrane (Showell et al.)	2018	Pooled RCTs	Various	Various	Pregnancy/live birth	Possible pregnancy benefit, low certainty; no clear live birth effect

So the dose is 4g. Let’s talk about why almost nobody takes it.

Dosage of Myo-Inositol for PCOS: The 4 Grams Nobody Tells You About

Why 2g twice daily is the research-backed standard

4,000mg of myo-inositol daily, split as 2g in the morning and 2g in the evening. That’s it. That’s the protocol behind the majority of positive trials, and if you take away one practical thing from this article, make it that number.

Why split it? Inositol absorption is saturable and the half-life is relatively short. Dosing twice daily keeps plasma levels elevated more consistently than one big hit, and it reduces the chance of osmotic loose stool.

The 40:1 myo to D-chiro ratio and when to deviate

Nordio and Proietti’s 2012 work compared myo-inositol alone against a combination formulated at the physiological plasma ratio of 40:1 myo to DCI. The combination came out ahead on metabolic and hormonal endpoints. That ratio became the industry standard, which in practice means 3,600mg myo-inositol plus 90mg D-chiro-inositol.

Why 40:1 and not the ovarian 100:1? Because the researchers modelled on plasma, the compartment a supplement actually enters first.

Why high-DCI formulas can backfire

This is the part the market gets wrong, and it matters.

Carlomagno, Unfer and Roseff described what they called the D-chiro-inositol paradox: in ovarian tissue, escalating DCI appears to worsen oocyte quality above a certain threshold, presumably by pushing the follicular myo:DCI ratio even further from physiological. Remember, the PCOS ovary already looks DCI-overloaded.

So a product marketed as “high D-chiro for serious insulin resistance” at, say, a 5:1 or 2:1 ratio may help your muscle tissue while doing your follicles no favours. If fertility is your goal, I’d stick to 40:1 or myo-inositol alone and treat aggressive DCI formulas with suspicion.

Lean versus overweight PCOS dosing

Honest answer: the trials didn’t stratify dosing by body size, and 4g was given regardless of BMI. Some clinicians push toward the upper end (and occasionally 6g) in women with higher body weight and marked insulin resistance, on the logic of distribution volume. That’s reasonable extrapolation, not evidence. Lean PCOS with normal insulin markers has thinner data overall, and if your androgens are primarily adrenal in origin, I’d temper expectations considerably.

Timing, food, and splitting doses

• Take it with or near meals if your stomach is sensitive. Fasted is fine for most people.
• Breakfast and dinner is the simplest split and mirrors trial protocols.
• Taking the evening dose earlier (with dinner, not at bedtime) avoids any mild gut activity waking you.
• Consistency beats precision. Same two times daily, every day.

Powder versus capsules versus gummies

At 4g daily, powder wins and it isn’t close. Myo-inositol is faintly sweet, dissolves easily in water, and costs a fraction of encapsulated versions. One level teaspoon is roughly 2g on most products (weigh it once to confirm).

Capsules typically deliver 500 to 1,000mg each, so you’re swallowing four to eight per day. Doable, expensive, annoying.

Gummies are the worst option available. Most deliver 500mg or less with added sugar or sugar alcohols, meaning you’d need eight gummies to hit the trial dose while eating candy for a condition driven by insulin resistance. I’d skip them entirely.

Non-responders and higher doses

Roughly 30 to 40% of women don’t respond adequately to standard-dose inositol, a phenomenon researchers have labelled inositol resistance. Emerging protocols explore higher doses (6 to 8g, occasionally more in specific insulin-resistance research) and, more interestingly, co-administration with alpha-lactalbumin, a whey-derived protein. Monastra and colleagues (2018) reported that adding alpha-lactalbumin improved inositol absorption and converted a meaningful share of previous non-responders into responders, apparently by improving intestinal permeability to inositol.

That’s a genuinely useful lead if you’ve done six honest months at 4g with nothing to show.

What to stack it with

• Folic acid / folate: used alongside inositol in nearly every single trial, typically 400mcg. If you’re trying to conceive you should be taking it anyway. Easiest co-factor decision you’ll make.
• Vitamin D: deficiency is common in PCOS and correlates with worse insulin resistance. Correcting a genuine deficiency is worthwhile. Megadosing a normal level isn’t.
• Berberine: real insulin-sensitising data in PCOS (Wei et al., 2012, among others), with AMPK activation as its mechanism. Also real drug interaction potential. Not a casual add-on.
• N-acetylcysteine (NAC): compared favourably with metformin for ovulation in some trials. Evidence is moderate, cost is low.
• Magnesium: deficiency is widespread and it has a legitimate role in insulin signalling. Modest expectations.

Cost reality check

Bulk myo-inositol powder at a proper 4g/day runs roughly $15 to $40 per month depending on brand and whether you buy the 40:1 blend. For context, that’s less than most useless PCOS “hormone balance” blends charge for 300mg of nothing.

How Long Until Myo-Inositol for PCOS Works? A Realistic Timeline

Weeks 1 to 4: mostly nothing (and that’s normal)

You will probably feel no dramatic change. Trials ran 12 to 24 weeks and reported primary outcomes at three months. Judging this supplement at three weeks is like weighing yourself mid-workout.

What some women do notice early: fewer afternoon sugar crashes, less of that post-lunch urge to lie down, slightly steadier appetite. Anecdotal, plausible given the insulin mechanism, not guaranteed.

Weeks 4 to 8: insulin markers and cravings

This is when metabolic changes start becoming measurable. If you retest fasting insulin and HOMA-IR around week eight, you may see movement. Carbohydrate cravings easing is the most commonly reported subjective shift in this window.

Your cycle probably hasn’t changed yet. Be patient.

Weeks 8 to 12: cycle changes and ovulation

Here’s the payoff window. Ovulation restoration in the trials clustered at 8 to 12 weeks. Cycle length tends to shorten progressively rather than snapping to 28 days: a 90-day cycle might become 60, then 45, then 35. Luteal phases lengthen. LH strips start producing actual peaks instead of the ambiguous smudge that makes PCOS testing so maddening.

Months 3 to 6: androgen symptoms, acne and hair

Skin and hair lag badly, and the reason is purely structural. A terminal hair follicle runs an anagen growth phase measured in months, so even if your androgens dropped in week ten, the hairs already in the pipeline keep growing. Realistic timeline for visible hirsutism change: four to six months minimum, and often longer.

Acne usually moves faster than hair, with improvement common around months three to four as skin turns over.

When to call it and try something else

Here’s my decision rule, stated plainly: six months at a genuine 4,000mg daily with no change in cycle length, no ovulation on testing, and no movement in labs means you’re likely an inositol non-responder. That’s a documented category, not a personal failure. At that point the options are adding alpha-lactalbumin, trialling a higher dose, or moving to metformin, letrozole, or whatever your situation calls for.

But “a genuine 4g” is doing a lot of work in that sentence. Before you conclude it failed, check your actual intake. I’ve lost count of the number of people who “tried inositol” at 1g.

What to actually track

Don’t rely on vibes. Track:

• Cycle length, first day to first day, in an app or a notebook
• Ovulation confirmation, via LH strips (test twice daily around expected ovulation) or basal body temperature, ideally both
• Fasting insulin and HOMA-IR, baseline and at three months
• Free testosterone and SHBG, not just total testosterone, since free T is where the action is
• AMH, baseline and at six months, if it was elevated and worrying you
• Before-and-after photos for skin and hair, same lighting, same angle, monthly (you will not remember what month one looked like)

Baseline labs before you start are the single most useful thing you can do. Without them, you’re left guessing in month four whether anything happened at all.

Side Effects and Safety: What 4 Grams of Myo-Inositol for PCOS Actually Feels Like

I’ll be straight: this is one of the cleaner safety profiles I’ve looked at in the supplement world. Not spotless. But close.

The GI side effects and the dose threshold

Across the PCOS trials, adverse events at 2g to 4g daily were rare and mild. The signal that keeps coming up in the literature is that gastrointestinal complaints cluster at much higher intakes, roughly above 12g a day, which is three times what anyone takes for PCOS. Early tolerability work on inositol in psychiatric research (where people were taking 12g to 18g daily) found nausea and loose stools showing up at those doses, and that’s where the ceiling sits.

At 4g, the complaints I hear most often are mild and short-lived: a bit of gas, slightly looser stools, a vaguely unsettled stomach in the first week or two.

The fix is almost always mechanical. Split the dose (2g morning, 2g evening), take it with food rather than on an empty stomach, and start at 2g for the first week before going to 4g. Nine times out of ten that resolves it within a fortnight.

Nausea, headaches and lightheadedness

Headaches get reported occasionally and usually fade. The more interesting one is lightheadedness, particularly in the first few weeks, particularly if you’re taking it on an empty stomach in the morning.

My read on that: it’s the insulin sensitivity improvement doing its job. If your cells suddenly become better at pulling glucose in, you can dip lower than you’re used to. The practical answer is to stop taking it fasted, pair the morning dose with a protein-containing breakfast, and see if it disappears. It usually does.

Pregnancy and breastfeeding data

This matters because a huge chunk of women reading about inositol are trying to conceive.

Inositol has actually been studied during pregnancy, not just before it. D’Anna and colleagues ran a series of trials in Italy using 2g of myo-inositol twice daily in pregnant women at elevated risk of gestational diabetes, published in Diabetes Care (2013 and 2015), and found reduced GDM incidence versus placebo. That’s a reassuring context: researchers were comfortable enough with the safety profile to dose pregnant women for months.

Breastfeeding data is thinner. Inositol is naturally present in human milk at meaningful concentrations, which is suggestive rather than conclusive.

Blood sugar medication interactions

Here’s where you need to pay actual attention. Myo-inositol lowers insulin resistance. Metformin lowers insulin resistance. GLP-1 agonists lower glucose. Exogenous insulin, obviously, lowers glucose.

Stack them and the effects are additive. For most women on metformin, adding inositol is fine and arguably complementary (several trials combined them). But if you’re on insulin or a sulfonylurea, you’re in territory where glucose monitoring matters, because hypoglycaemia is a real possibility rather than a theoretical one.

Who should be cautious

The one interaction I’d flag hardest is lithium. Inositol depletion in the brain is thought to be part of how lithium works for bipolar disorder, so supplementing inositol at gram doses works against the mechanism. There are case reports of inositol triggering manic symptoms in people with bipolar disorder. If that’s you, this isn’t a casual “try it and see” supplement.

Also worth caution: anyone with a history of hypoglycaemia, and anyone with kidney impairment severe enough that clearance of anything is a question.

Does it affect thyroid or mood medication?

Thyroid is an interesting one. Myo-inositol combined with selenium has been studied in subclinical hypothyroidism with Hashimoto’s, with some trials showing TSH reductions. So it doesn’t interfere with levothyroxine, but it might nudge your numbers, which means retesting thyroid labs a few months in isn’t a bad idea if you’re medicated.

SSRIs? No meaningful interaction signal. The exception remains lithium.

And on long-term use: do you need to cycle it? No. The trials ran continuously for six, twelve, even twenty-four months without accumulating safety problems. Cycling advice for inositol is invented, not evidenced.

One last thing. “Natural” doesn’t mean inert. Inositol is a molecule with a mechanism, and anything with a mechanism can interact with something. It just happens that this particular molecule has an unusually forgiving profile.

Myo-Inositol for PCOS vs the Alternatives: An Honest Comparison

This is the section most articles dodge, because comparing honestly means admitting inositol isn’t always the winner.

Myo-inositol vs metformin

Head-to-head trials exist, and they’re more favourable to inositol than I expected going in. Raffone and colleagues (2010) randomised women with PCOS to 4g myo-inositol plus folic acid or 1,500mg metformin, and ovulation restoration came out at roughly 65% on inositol versus 50% on metformin, with pregnancy rates of about 30% versus 18%. Small trial. Open label. Treat with appropriate caution.

But the pattern holds across other comparisons: similar ovulation outcomes, with metformin pulling ahead on hard metabolic markers like HbA1c and (modestly) weight.

Where inositol wins decisively is tolerability. Metformin’s GI dropout rate in real-world practice runs somewhere in the 10% to 25% range depending on the population and whether extended-release was used. Inositol’s dropout rate in the PCOS trials is close to nothing.

So: metformin is the stronger drug. Inositol is the one people actually keep taking.

Myo-inositol vs D-chiro-inositol alone

DCI got its moment of fame from Nestler’s 1999 New England Journal of Medicine paper, which showed improved insulin sensitivity and ovulation in women with PCOS. Supplement companies ran with it.

Then the follicular fluid work complicated the story. Research into the ovarian environment found that healthy follicular fluid is dominated by myo-inositol at a very high ratio to DCI, and that pushing DCI too high appears to work against oocyte quality. Isabella and Raffone’s 2012 paper in the Journal of Ovarian Research asked the question directly in its title (“Does ovary need D-chiro-inositol?”) and the answer they landed on was: not much, and not more.

My position: for fertility goals, DCI-dominant or DCI-only products are the wrong tool. Myo-inositol first, DCI as a minority partner at 40:1, or not at all.

Myo-inositol vs berberine

Berberine is genuinely impressive metabolically. Wei et al. published a trial in the European Journal of Endocrinology (2012) comparing berberine with metformin in PCOS, and berberine held its own on insulin resistance while outperforming on lipid profile.

The problem is reproductive safety. Berberine crosses into questionable territory for anyone who might become pregnant, it has meaningful drug interactions through CYP enzymes, and it’s contraindicated in pregnancy. If pregnancy is on the table in the next year, I wouldn’t choose berberine over inositol. If it isn’t, and your main issue is dyslipidaemia plus insulin resistance, berberine becomes a reasonable contender.

Myo-inositol vs the combined oral contraceptive pill

Let me be clear about what the pill does. It suppresses ovarian androgen production and gives you a predictable withdrawal bleed. For acne and hirsutism, it works, often well.

What it doesn’t do is improve insulin signalling, and some formulations worsen insulin resistance. It also doesn’t treat PCOS. It manages the visible output while the underlying metabolic picture carries on unchanged, and the moment you stop, the symptoms return.

And it’s obviously not a fertility option.

Myo-inositol alongside spironolactone or letrozole

No conflict with either. Letrozole is the evidence-based first-line ovulation induction agent (the PPCOS II trial published in NEJM in 2014 settled that against clomiphene), and there’s no mechanistic reason inositol would interfere. Several clinics use inositol as metabolic background support during induction cycles.

Spironolactone works on androgen receptors, inositol works on insulin signalling. Different lanes.

Comparison table

Option	Ovulation benefit	Side effect burden	Monthly cost	Evidence strength
Myo-inositol 4g (40:1)	Moderate to good	Very low	£8 to £25	Moderate (many small RCTs, meta-analyses, weak on live birth)
Metformin 1,500 to 2,000mg	Moderate to good	Moderate to high (GI)	£5 to £15	Strong (decades of data)
D-chiro-inositol alone	Unclear, possibly negative for oocytes	Very low	£20 to £40	Weak
Berberine 1,000 to 1,500mg	Limited direct data	Moderate (GI), interactions	£15 to £30	Moderate for metabolic, weak for fertility
Combined pill	None (suppresses ovulation)	Moderate	£0 to £15	Strong for symptom control
Letrozole	Strong	Low to moderate	Prescription	Strong

My actual opinion, stated plainly: for insulin-resistant PCOS where pregnancy is the goal, myo-inositol is the most sensible first move, because the downside is nearly nil and the upside is well documented. For severe metabolic disease, prediabetes creeping into diabetes, or significant weight-related complications, metformin still wins and I wouldn’t argue otherwise.

PCOS Phenotypes: Why Myo-Inositol for PCOS Works Brilliantly for Some Women and Does Nothing for Others

This is the part competitors skip entirely, and it’s the most useful thing in this article.

Roughly 65% to 70% of women with PCOS have measurable insulin resistance. That’s the population inositol was validated in. Which means, logically, somewhere between a quarter and a third of women with PCOS are taking a supplement whose entire mechanism targets a problem they may not have.

Insulin-resistant PCOS (the best responders)

High fasting insulin, elevated HOMA-IR, often (not always) higher BMI, skin tags, acanthosis nigricans, intense carb cravings, post-meal crashes. Elevated LH:FSH ratio is common.

If that’s your picture, inositol is working directly upstream of your problem. Lower insulin means less LH-driven ovarian androgen output, better SHBG, better follicular development. This is where the trial results came from.

Lean PCOS

Here’s the trap. Normal BMI, normal fasting glucose, and a GP who says “your bloods are fine.”

Fasting glucose is a terrible screening test for compensatory hyperinsulinaemia. Your pancreas can be pumping out double the normal insulin to keep that glucose number pretty, and you’d never know. A two-hour OGTT with insulin levels measured at each timepoint is far more informative, and lean women with PCOS frequently light that test up.

So lean PCOS can absolutely respond. You just need better testing to know whether you’re a candidate.

Post-pill and adrenal PCOS

Adrenal-driven presentations (elevated DHEA-S, normal fasting insulin, normal HOMA-IR, androgens coming from the adrenal glands rather than the ovaries) are unlikely to respond strongly to inositol. That’s a mechanistic prediction, not a criticism of the supplement. You’re treating insulin signalling in someone whose insulin signalling is fine.

Post-pill presentations are murkier, because some resolve on their own over 6 to 12 months as the HPO axis recovers. Inositol won’t hurt. Attributing recovery to it is a mistake.

Inflammatory PCOS

Chronic low-grade inflammation shows up across PCOS generally, and inositol has some anti-inflammatory signal in the literature, but it’s secondary. If your CRP is elevated, you’ve got gut symptoms, joint pain and fatigue dominating the picture, inositol alone is unlikely to be the answer.

How to figure out which one you are

Ask for this panel. Baseline, before you start anything:

• Fasting insulin and fasting glucose (calculate HOMA-IR)
• Two-hour OGTT with insulin at 0, 60 and 120 minutes
• Total testosterone, free testosterone, SHBG
• DHEA-S
• AMH
• LH and FSH (day 3 if you’re cycling)
• HbA1c
• Vitamin D
• Thyroid panel including antibodies
• hs-CRP

One more wrinkle. There’s a documented phenomenon of inositol non-response, and one proposed explanation is gut microbial degradation: certain bacteria metabolise inositol before it’s absorbed, so you take 4g and your bloodstream sees a fraction of it. That’s the rationale behind alpha-lactalbumin co-formulations, which Monastra and colleagues studied as a way to improve absorption in previously unresponsive patients. It’s a plausible mechanism with modest evidence, and it’s the first thing I’d try before abandoning inositol entirely.

How to Choose a Myo-Inositol Supplement Without Getting Ripped Off

The inositol market is full of products that cannot deliver a therapeutic dose, priced as though they can.

Red flags on the label

• Proprietary blends. If the label says “Inositol Complex 1,200mg” without breaking out myo and DCI separately, you cannot dose it. Walk away.
• Serving sizes under 2g. A 500mg capsule means eight capsules a day. Do that maths before you buy.
• DCI-dominant ratios. Covered above. Wrong direction for fertility.
• The 14-ingredient “PCOS blend.” Berberine 50mg, chromium 20mcg, cinnamon 100mg, NAC 200mg, inositol 600mg. Every ingredient at a fraction of its studied dose. These exist to look impressive on an ingredient list, not to work.

Ratio claims that don’t add up

A true 40:1 formula at 4g total means 3,900mg myo-inositol and 97.5mg DCI, or close enough (most products use 3,600:90). Do the division yourself. I’ve seen products advertise “40:1” while delivering ratios closer to 10:1, and nobody checks.

Third-party testing and what to look for

GMP-certified manufacturing, third-party identity and purity testing, and a company that will actually send you a certificate of analysis if you email and ask. That last one is the real test. Ask. The response tells you plenty.

Why I’d skip the gummies

Two reasons. First, gummies almost never reach therapeutic doses, because you can’t physically fit 2g of inositol into a pleasant chewable without it becoming a boiled sweet. Second, they typically carry 4g to 8g of added sugar per serving.

Giving sugar to someone with insulin-resistant PCOS to improve their insulin resistance is, let’s say, counterproductive.

Cost per effective dose, not cost per bottle

Worked example, because this is where people get caught:

Product A: 120 capsules, 500mg each, £14.99. You need 8 capsules daily for 4g. That’s 15 days per bottle. £1.00 per day, £30 per month.

Product B: 500g unflavoured powder (40:1), £22.99. At 4g daily that’s 125 days. £0.18 per day, £5.50 per month.

Same molecule. Product A costs five and a half times more. The capsules looked cheaper.

Inositol powder is mildly sweet and dissolves readily in water, which makes the powder format genuinely easy to take (this isn’t creatine). Just check that “flavoured” versions aren’t smuggling in sucralose or a pile of sugar alcohols you’ll regret.

Folic acid or methylfolate inclusion is a reasonable bonus, since nearly every trial paired inositol with 400mcg of folic acid. Just don’t pay a premium for it.

What Myo-Inositol Won't Fix (And What to Do About Those Things)

It isn’t a weight-loss supplement

I need to be blunt here because the marketing has gotten out of hand. BMI changes in the inositol trials were small, inconsistent, and often not statistically significant. The Cochrane-style reviews don’t support a meaningful weight loss effect.

Anyone selling inositol as a fat loss pill is overreaching, full stop. It may make weight loss slightly easier by improving insulin sensitivity and reducing cravings. It will not do the work for you.

Diet and resistance training still do the heavy lifting

Resistance training improves insulin sensitivity in PCOS through a glucose uptake pathway that’s partly independent of insulin, which means it stacks with inositol rather than competing with it. Two or three sessions a week moves the needle. I’d rate it as more impactful than any supplement on this page.

Protein at every meal (aim 25g to 35g), fibre targets you actually hit, and meal sequencing (vegetables and protein before the carbohydrate portion) blunt glucose excursions in ways that are measurable on a CGM.

And please don’t crash diet. Aggressive caloric restriction reliably disrupts cycle regularity, which is precisely the outcome you’re trying to fix.

Sleep, cortisol and the overlooked variables

Obstructive sleep apnoea is dramatically underdiagnosed in PCOS. The rates are far higher than in matched controls, independent of BMI in some analyses, and untreated apnoea wrecks insulin sensitivity overnight. If you snore, wake unrefreshed, or your partner has mentioned breathing pauses, get a sleep study before you spend another six months on supplements.

Chronic sleep restriction alone (five hours a night for a week) measurably impairs insulin sensitivity in healthy people. You cannot supplement your way out of that.

When to escalate to medical treatment

Specific triggers, not vague ones:

• No period for three months or more (endometrial protection becomes the priority)
• Abnormal or heavy bleeding, or a long history of amenorrhoea without evaluation
• HbA1c in the diabetic range
• 12 months of trying to conceive without success (6 months if you’re over 35)
• Rapid-onset virilisation, which needs investigating for other causes

My Verdict: Who Should Actually Try Myo-Inositol

The case for trying it

For insulin-resistant PCOS, particularly with fertility goals, I think myo-inositol is a strong first-line trial. The risk-to-reward ratio is unusually favourable: minimal side effects, roughly £6 to £25 a month, multiple randomised trials and meta-analyses showing improved ovulation and insulin markers, and a mechanism that makes biological sense rather than being reverse-engineered from a marketing brief.

This is one of the few supplements where I’d argue not trying it is the harder position to defend.

The case against

I’ll be straight about where the evidence is weakest, because it is weak in places.

Live birth rate data is unconvincing. Cochrane-style reviews have repeatedly concluded that while ovulation and biochemical markers improve, the evidence for live births and clinical pregnancy is low quality. Many trials are small, short, open label, and conducted by research groups with commercial ties to inositol formulations. That’s not disqualifying. It’s a reason to hold your expectations loosely.

And if your insulin markers are normal, the mechanism simply may not apply to you.

A simple 12-week protocol to test it properly

1. Get baseline labs. Fasting insulin, HOMA-IR, free and total testosterone, SHBG, DHEA-S, AMH, HbA1c, vitamin D. Non-negotiable.
2. Track your current cycle length for at least one cycle before starting, if you’re cycling at all.
3. Take 4g daily of myo-inositol in a 40:1 ratio with DCI, split as 2g morning and 2g evening, with food. Add 400mcg folic acid.
4. Run it for 12 to 16 weeks minimum. Ovulatory changes often appear around weeks 8 to 12. Skin around months 3 to 4. Hair takes 4 to 6 months or more.
5. Confirm ovulation, don’t assume it. LH strips twice daily around mid-cycle, plus basal body temperature.
6. Repeat the labs at week 12.
7. Decide on data. Improvement in cycle length, confirmed ovulation, or falling insulin and free testosterone means continue. Nothing at all after six genuine months at 4g means consider alpha-lactalbumin, or move on to metformin or letrozole.

Final honest caveat

Some women get their first spontaneous period in two years on this stuff. Others take it faithfully for six months and get nothing. Both outcomes are in the literature, and I can’t tell you in advance which you’ll be.

What I can tell you is that it’s cheap, it’s well tolerated, and the test takes three months. That’s a reasonable bet.

Frequently Asked Questions

Q: What does myo-inositol do for PCOS? Myo-inositol improves how your cells respond to insulin, which lowers circulating insulin, reduces ovarian testosterone production, and helps restore ovulation. In trials it improves cycle regularity, lowers free testosterone, raises SHBG, and improves insulin resistance markers like HOMA-IR. It also supports oocyte quality, since myo-inositol is the dominant inositol in healthy follicular fluid.

Q: How does myo-inositol work for PCOS? It acts as a precursor to inositol phosphoglycan second messengers, the molecules that carry insulin’s signal inside the cell. Many women with PCOS have a defect in converting myo-inositol into these messengers, so insulin signalling is impaired despite normal insulin levels. Supplementing bypasses the shortfall. Less insulin means less LH-driven androgen production in the ovary, which allows normal follicle development.

Q: Is myo-inositol safe to take long term for PCOS? Yes, based on current evidence. Trials have run 6 to 24 months at doses up to 4g daily with rare, mild side effects. GI complaints mainly appear above 12g per day. There’s no need to cycle it. The main exceptions are people taking lithium (inositol works against its mechanism) and anyone on insulin or sulfonylureas, where additive glucose lowering needs monitoring.

Q: What is the best dosage of myo-inositol for PCOS? 4,000mg (4g) of myo-inositol daily, split into two 2g doses, is the dose used in most positive trials. If using a combination product, the ratio should be 40:1 myo-inositol to D-chiro-inositol, meaning roughly 3,600mg myo plus 90mg DCI. Doses of 1g or 2g daily, which many commercial products deliver, are below the therapeutic threshold.

Q: How long does myo-inositol take to work for PCOS? Insulin markers often shift within 8 to 12 weeks. Cycle changes and ovulation typically appear between weeks 8 and 16. Acne usually improves around months 3 to 4. Hirsutism takes 4 to 6 months minimum because of the hair growth cycle. Give it a full 3 months before judging, and 6 months before concluding it has failed.

Q: Should I take myo-inositol alone or with D-chiro-inositol? Either works, but if you combine them, use a 40:1 ratio. That reflects the physiological ratio found in plasma. Avoid DCI-dominant or DCI-only products if fertility is your goal, because follicular fluid research suggests excess DCI may impair oocyte quality. Myo-inositol alone at 4g is a perfectly reasonable choice.

Q: Can myo-inositol help me get pregnant with PCOS? It improves ovulation rates in randomised trials, and ovulation is the prerequisite for conception. Some trials show higher pregnancy rates, including a head-to-head comparison against metformin. But the evidence for live birth rates specifically remains low quality, so treat it as a supportive measure rather than a fertility treatment. It’s often combined with letrozole or used before medicated cycles.

Q: Is myo-inositol better than metformin for PCOS? Not better across the board. Ovulation outcomes are comparable in head-to-head trials, and inositol is far better tolerated (metformin GI dropout runs 10% to 25%). Metformin is stronger for HbA1c, significant insulin resistance and weight. My take: inositol first for mild to moderate insulin resistance with fertility goals, metformin for significant metabolic disease.

Q: Does myo-inositol cause weight loss in PCOS? Barely, and inconsistently. BMI changes in trials were small and often not statistically significant. It may make weight management easier by reducing insulin levels and cravings, but it is not a weight loss supplement and anyone marketing it that way is overstating the data.

Q: Can I take myo-inositol while on birth control or metformin? Yes to both. There’s no interaction with hormonal contraception, though the pill suppresses ovulation so you won’t see cycle benefits while on it. Combining with metformin is common and the effects are complementary, though the glucose-lowering is additive, so monitor if you also use insulin or a sulfonylurea.

Q: Does myo-inositol lower AMH and testosterone levels? Testosterone, yes. Multiple trials show reductions in free and total testosterone alongside increased SHBG. AMH reductions have been reported in several studies, likely reflecting reduced small follicle burden as ovarian function normalises. Expect changes over 3 to 6 months, not weeks, and recheck labs rather than guessing.

Q: Why isn’t myo-inositol working for me? Three common reasons. One, you’re underdosing (anything under 4g daily is the most frequent problem). Two, you haven’t given it long enough (under 12 weeks). Three, insulin resistance isn’t your primary driver, which is common in adrenal-dominant PCOS with elevated DHEA-S and normal fasting insulin. A fourth possibility is gut microbial degradation reducing absorption, which alpha-lactalbumin co-formulations may address.

Q: Should I take myo-inositol in the morning or at night? Split it: 2g in the morning and 2g in the evening. Inositol has a relatively short half-life, so splitting maintains steadier levels. Take it with food if you get nausea or lightheadedness. Some women find the evening dose helps sleep, which is a reasonable reason to weight it later in the day.

Q: Is myo-inositol safe during pregnancy? It has been studied during pregnancy, with 2g twice daily used in gestational diabetes prevention trials published in Diabetes Care, showing reduced GDM incidence without safety concerns. Many women continue it through the first trimester. Dosing during pregnancy is a decision to make with whoever is managing your care, since protocols differ.

The Short Version

Myo-inositol for PCOS is one of the rare supplements where the data is decent, the mechanism is understood, the price is low, and the side effect profile is close to nothing. That combination is unusual enough that I think it earns a trial in most cases of insulin-resistant PCOS.

But the dosing mistake is real, and it’s everywhere. Four grams a day. Split into two doses. 40:1 ratio if you’re combining. Twelve to sixteen weeks before you judge it.

Most women who say inositol didn’t work for them never actually took a therapeutic dose for a therapeutic length of time. Get your baseline labs, take the real dose, track your cycles properly, and retest in three months.

Then you’ll have an answer that belongs to you, not to a meta-analysis.

Frequently Asked Questions